Edition:
India

Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

50.55USD
20 Oct 2017
Change (% chg)

$-0.13 (-0.26%)
Prev Close
$50.68
Open
$50.65
Day's High
$50.66
Day's Low
$50.37
Volume
299,997
Avg. Vol
407,170
52-wk High
$50.95
52-wk Low
$30.90

Chart for

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 0.62
Market Cap(Mil.): $96,106.93
Shares Outstanding(Mil.): 1,962.56
Dividend: 0.47
Yield (%): 1.93

Financials

  Industry Sector
P/E (TTM): -- 30.44 16.24
EPS (TTM): -- -- --
ROI: -- 14.17 10.90
ROE: -- 15.52 14.09

Novo Nordisk takes aim at Eli Lilly with U.S. backing of new diabetes drug

WASHINGTON/COPENHAGEN Denmark's Novo Nordisk will take aim at Eli Lilly in the growing diabetes market after an advisory panel to the U.S. Food and Drug Administration (FDA) gave the green light to its semaglutide drug.

19 Oct 2017

Reuters Business News Schedule at 0830 GMT/430AM ET

China's Q3 economic growth slows as expected, property measures bite

19 Oct 2017

UPDATE 3-Novo Nordisk takes aim at Eli Lilly with U.S. backing of new diabetes drug

WASHINGTON/COPENHAGEN, Oct 19 Denmark's Novo Nordisk will take aim at Eli Lilly in the growing diabetes market after an advisory panel to the U.S. Food and Drug Administration (FDA) gave the green light to its semaglutide drug.

19 Oct 2017

BRIEF-Novo Nordisk VP says seeks market share from Eli Lilly with semaglutide

Oct 19 NOVO NORDISK CHIEF SCIENTIFIC OFFICER MADS KROGSGAARD THOMSEN SAYS IN INTERVIEW:

19 Oct 2017

BRIEF-Novo Nordisk VP says road is paved for timely US FDA approval of semaglutide

Oct 19 NOVO NORDISK CHIEF SCIENTIFIC OFFICER MADS KROGSGAARD THOMSEN SAID IN AN INTERVIEW:

19 Oct 2017

U.S. FDA panel backs approval of Novo Nordisk diabetes drug

WASHINGTON, Oct 18 Novo Nordisk A/S's new diabetes drug semaglutide is effective, reasonably safe and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.

19 Oct 2017

Novo Nordisk diabetes drug works; no heart risk-FDA review

Novo Nordisk A/S's closely watched diabetes drug semaglutide is effective, caused no heart risk, and carried only limited risk of sight problems, a preliminary review by the U.S. Food and Drug Administration concluded on Monday, sending the company's shares up 4 percent.

16 Oct 2017

UPDATE 1-Novo Nordisk diabetes drug effective, preliminary FDA review finds

Oct 16 Novo Nordisk A/S's closely watched diabetes drug semaglutide is effective, a preliminary review by the U.S. Food and Drug Administration concluded, sending the company's shares up 3.4 percent in premarket trading on Monday.

16 Oct 2017

FDA approves Novo Nordisk fast-acting insulin Fiasp

The U.S. Food and Drug Administration on Friday approved Novo Nordisk's fast-acting insulin to treat diabetes.

30 Sep 2017

U.S. FDA approves Novo Nordisk fast-acting insulin Fiasp

Sept 29 The U.S. Food and Drug Administration on Friday approved Novo Nordisk's fast-acting insulin to treat diabetes.

29 Sep 2017

Competitors

  Price Chg
Sanofi SA (SASY.PA) €84.44 +0.63
Eli Lilly and Co (LLY.N) $87.23 +0.87

Earnings vs. Estimates